• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经鼻内给予花粉特异性免疫治疗对日本柏花粉症的持续疗效。

Sustained effects of intralymphatic pollen-specific immunotherapy on Japanese cedar pollinosis.

机构信息

Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Osaka, Japan.

Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan.

出版信息

Rhinology. 2020 Jun 1;58(3):241-247. doi: 10.4193/Rhin19.301.

DOI:10.4193/Rhin19.301
PMID:32091032
Abstract

BACKGROUND

Intralymphatic immunotherapy (ILIT) for allergic patients requires only a few intralymphatic injections of the allergen. However, the effectiveness and safety for Japanese cedar pollinosis are unclear. The objectives of this study were to clarify whether and how long ILIT is effective for pollinosis, and its safety.

METHODS

In an open pilot investigation followed by a double-blind, placebo-controlled study, patients with Japanese cedar pollinosis received 3 intralymphatic inguinal injections of the pollen extracts before the first pollen season. The symptom medication score (SMS), nasal provocation testing and scoring visual analogue scale (VAS) were assessed after the first-third seasons.

RESULTS

(1) Although mild adverse events were induced at the injected site, severe adverse events were not noted. (2) During the latter part of the first season, ILIT-treated patients (n=12) tended to show improved SMS compared to placebo-treated (n=6) without statistical significance. When assessed by nasal provocation testing and VAS scoring after the first season, the effectiveness of ILIT was significant. (3) The effects of ILIT continued until the second or third season. (4) Neither allergen-specific antibodies nor Treg/Breg cells changed in the peripheral blood.

CONCLUSIONS

ILIT was safe and effective for Japanese cedar pollinosis. The clinical effects remained for 1-2 years.

摘要

背景

针对过敏患者的淋巴内免疫疗法 (ILIT) 仅需对过敏原进行几次淋巴内注射。然而,其对日本扁柏花粉症的有效性和安全性尚不清楚。本研究旨在明确 ILIT 对花粉症的有效性及其安全性。

方法

在一项开放性初步研究之后,进行了一项双盲、安慰剂对照研究,18 例日本扁柏花粉症患者在首个花粉季节前接受 3 次腹股沟淋巴内注射花粉提取物。在第一个至第三个季节后,评估症状药物评分 (SMS)、鼻激发测试和评分视觉模拟量表 (VAS)。

结果

(1) 尽管注射部位出现轻微不良反应,但未观察到严重不良反应。(2) 在第一个季节的后半段,与安慰剂治疗组(n=6)相比,ILIT 治疗组(n=12)的 SMS 有改善趋势,但无统计学意义。在第一个季节后进行鼻激发测试和 VAS 评分评估时,ILIT 的有效性显著。(3) ILIT 的作用持续到第二个或第三个季节。(4) 外周血中的过敏原特异性抗体和 Treg/Breg 细胞均未发生变化。

结论

ILIT 对日本扁柏花粉症安全且有效。临床效果可持续 1-2 年。

相似文献

1
Sustained effects of intralymphatic pollen-specific immunotherapy on Japanese cedar pollinosis.经鼻内给予花粉特异性免疫治疗对日本柏花粉症的持续疗效。
Rhinology. 2020 Jun 1;58(3):241-247. doi: 10.4193/Rhin19.301.
2
Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.局部免疫疗法:花粉性变应性鼻炎的一种有效且安全的替代治疗途径。
J Allergy Clin Immunol. 2013 Feb;131(2):412-20. doi: 10.1016/j.jaci.2012.10.056.
3
Intralymphatic immunotherapy for mountain cedar pollinosis: A randomized, double-blind, placebo-controlled trial.山雪松花粉症的淋巴内免疫治疗:一项随机、双盲、安慰剂对照试验。
Ann Allergy Asthma Immunol. 2020 Sep;125(3):311-318.e2. doi: 10.1016/j.anai.2020.04.030. Epub 2020 May 11.
4
[Lowered effectiveness of immunotherapy for cypress pollinosis by using Japanese cedar pollen extract].[使用日本柳杉花粉提取物降低免疫疗法对柏树花粉症的疗效]
Arerugi. 2008 May;57(5):558-61.
5
Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination.免疫疗法对日本柳杉花粉症在柳杉和柏树花粉传播季节的临床效果。
Auris Nasus Larynx. 1997 Apr;24(2):163-70. doi: 10.1016/S0385-8146(96)00028-4.
6
Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.局部免疫疗法改善花粉过敏症:一项为期 3 年的随机安慰剂对照试验。
J Allergy Clin Immunol. 2021 Mar;147(3):1011-1019. doi: 10.1016/j.jaci.2020.07.002. Epub 2020 Jul 15.
7
Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.花粉诱导的鼻结膜炎的淋巴内免疫疗法:一项双盲安慰剂对照试验。
Respir Res. 2016 Jan 27;17:10. doi: 10.1186/s12931-016-0324-9.
8
Allergen-specific subcutaneous immunotherapy for Japanese cedar pollinosis decreases the number of metachromatic cells and eosinophils in nasal swabs during the preseason and in season.变应原特异性皮下免疫治疗对日本杉花粉症患者在花粉季节前和花粉季节期间,可减少鼻拭子中变色细胞和嗜酸性粒细胞的数量。
Immun Inflamm Dis. 2020 Sep;8(3):258-266. doi: 10.1002/iid3.301. Epub 2020 Apr 2.
9
Safety and efficacy of a new regimen of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a prospective, randomized, open-label study.Cry j 1-半乳甘露聚糖缀合物短期口服免疫疗法新方案治疗日本雪松花粉症的安全性和有效性:一项前瞻性、随机、开放标签研究。
Allergol Int. 2015 Apr;64(2):161-8. doi: 10.1016/j.alit.2014.10.009. Epub 2015 Jan 12.
10
Safety and efficacy of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a randomized controlled trial.Cry j 1-半乳甘露聚糖缀合物短期口服免疫治疗日本雪松花粉症的安全性和有效性:一项随机对照试验。
Sci Rep. 2017 Apr 11;7:46142. doi: 10.1038/srep46142.

引用本文的文献

1
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens.打破常规:针对环境过敏原的非传统变应原免疫疗法
Immunotherapy. 2024;16(18-19):1153-1169. doi: 10.1080/1750743X.2024.2408216. Epub 2024 Oct 9.
2
Evaluation of Intralymphatic Immunotherapy in Allergic Rhinitis Patients: A Systematic Review and Meta-analysis.评价变应性鼻炎患者淋巴免疫疗法的疗效:系统评价和荟萃分析。
Mediators Inflamm. 2023 May 8;2023:9377518. doi: 10.1155/2023/9377518. eCollection 2023.
3
Immunology of allergen immunotherapy.
变应原免疫疗法的免疫学
Immunother Adv. 2022 Nov 25;2(1):ltac022. doi: 10.1093/immadv/ltac022. eCollection 2022.
4
Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update.《变应性鼻炎变应原特异性免疫治疗中国专家共识:2022年版》
Allergy Asthma Immunol Res. 2022 Nov;14(6):604-652. doi: 10.4168/aair.2022.14.6.604.
5
Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review.人类变应原特异性免疫疗法的最新进展:一项系统综述。
Immune Netw. 2022 Feb 7;22(1):e12. doi: 10.4110/in.2022.22.e12. eCollection 2022 Feb.
6
Diagnosis and Treatment of Local Allergic Rhinitis.局部变应性鼻炎的诊断与治疗
Pathogens. 2022 Jan 9;11(1):80. doi: 10.3390/pathogens11010080.
7
Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: A systematic review and meta-analysis.淋巴管内免疫疗法治疗变应性鼻炎的疗效与安全性:一项系统评价和荟萃分析。
Clin Transl Allergy. 2021 Aug 17;11(6):e12055. doi: 10.1002/clt2.12055. eCollection 2021 Aug.
8
Next-Generation Allergen-Specific Immunotherapy for Japanese Cedar Pollinosis Using Molecular Approaches.利用分子方法的日本雪松花粉症下一代过敏原特异性免疫疗法
Immunotargets Ther. 2021 Jul 2;10:213-224. doi: 10.2147/ITT.S276874. eCollection 2021.
9
Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial.淋巴内免疫疗法联合酪氨酸吸附变应原:一项双盲、安慰剂对照试验。
Respir Res. 2021 Jun 4;22(1):170. doi: 10.1186/s12931-021-01766-0.